NEW YORK, March 17 (GenomeWeb News) - Lynx Therapeutics has cut 15 percent of its workforce, the Hayward, Calif.-based company said today.
The layoffs leave the company with 76 employees.
Lynx is commercializing its Massively Parallel Signature Sequencing analysis platform.
Kevin Corcoran, the company's chief executive officer, said Lynx plans to expand new applications for its DNA sequencing services, and continue to develop its gene-expression services.
"We believe we are well-positioned to execute on our strategy, while keeping costs under control," he said in a statement. "We appreciate the contributions made by former employees and offer them our sincere thanks."